We recently reported that the prevalence of hyperandrogenic disorders is markedly increased in women with type 1 diabetes (1). The polycystic ovary syndrome (PCOS) defined by endocrine criteria was found in 18.8% of the type 1 diabetic women who followed-up in our hospital (1), as compared with the 6.5% prevalence in nondiabetic women from similar ethnic and genetic backgrounds (2). The prevalence of hirsutism in type 1 diabetic women was 30.6% (1), which is markedly higher than the 7.1% prevalence of hirsutism found in nondiabetic women (2). In the present study, we evaluated the adrenal and ovarian steroidogenic profiles of hyperandrogenic and nonhyperandrogenic type 1 diabetic women and compared them with those of nondiabetic hyperandrogenic women and healthy control subjects. A total of 24 women with type 1 diabetes were recruited for the study (1). Fourteen diabetic patients (age [mean ± SD] 20.6 ± 4.0 years, BMI 24.8 ± 2.9 kg/m2) were considered to have hyperandrogenism. The other 10 women with type 1 diabetes (age 19.0 ± 3.0 years, BMI 23.3 ± 2.6 kg/m2) had no evidence of clinical or biochemical hyperandrogenism and had regular menstrual cycles. Both groups of type 1 diabetic patients had similar HbA1c levels (7.4 ± 1.2 vs 7.8 ± 1.2% in nonhyperandrogenic and hyperandrogenic diabetic patients, respectively, F = 0.591, P = 0.450), and there were no differences in the mean daily insulin dose used for their treatment (0.82 ± 0.27 vs. 0.66 ± 0.28 U · kg−1 body wt · day−1 in nonhyperandrogenic and hyperandrogenic diabetic patients, F = 1.875, P = 0.185). A total of 86 nondiabetic women were included as control subjects. Nondiabetic women were matched for BMI and age with the diabetic patients to avoid any influence of age and obesity on the results. Thirteen …
No takes yet. Share an insight, caveat, or question.
Roldán et al. (2001) studied this question.